ArticleCritical care (London, England)2019

Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial.

Mathilde Scarton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.